Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02954601 · ClinicalTrials.gov registry record · Phase 2

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

A Phase 2 study, sponsored by Oramed.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target

NCT02954601: Completed Phase 2 study, sponsored by Oramed.

NCT02954601 is a Phase 2 study that has completed, run by Oramed. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02954601, a Phase 2 study, has completed, sponsored by Oramed.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target

Study Summary

This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive. Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.

Primary Outcome

Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)

Interventions

  • OTHER Placebo
  • DRUG ORMD-0801 (qd)
  • DRUG ORMD-0801 (bid)
  • DRUG ORMD-0801 (tid)

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2016-10
Est. Completion 2017-03-15
Phase Phase 2
Oramed

11 total trials

What the finished NCT02954601 record still lists

NCT02954601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT02954601 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02954601 about?

NCT02954601 is a clinical study titled "A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus". This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive. Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in....

What is the current status of trial NCT02954601?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2016-10. Estimated completion is 2017-03-15.

What interventions are being tested in trial NCT02954601?

The interventions under investigation include: Placebo (OTHER), ORMD-0801 (qd) (DRUG), ORMD-0801 (bid) (DRUG), ORMD-0801 (tid) (DRUG).

Who is sponsoring clinical trial NCT02954601?

This trial is sponsored by Oramed, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02954601's enrollment target sits among peer trials

31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02954601, the US trial registry maintained by the National Library of Medicine. NCT02954601 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.